



2 August 2013
EMA/CHMP/241120/2013
Press Office

Guidelines and concept papers

Adopted during the CHMP meeting 22-25 July 2013

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under [Regulatory/Human/Scientific guidelines](#). Documents for public consultation will also be available under [Document search/Public consultations](#).

Central Nervous System Working Party (CNSWP)

Reference number	Document	Status
EMA/CHMP/40105/2013	Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS)	6-month public consultation

Pharmacokinetics Working Party (PKWP)

Reference number	Document	Status
CHMP/PKWP/423137/2013	Concept paper on the development of product-specific guidance on demonstration of bioequivalence	2-month public consultation

Quality Working Party (QWP)

Reference number	Document	Status
EMA/414248/2013	Guideline on Pharmaceutical Development of Medicines for Paediatric Use <ul style="list-style-type: none">Overview of comments (EMA/414249/2013)	adopted



Safety Working Party (SWP)

Reference number	Document	Status
EMA/704345/2012	Work plan for the Safety Working Party 2013	adopted
EMA/CHMP/CVMP/JEG-3Rs/443879/2012	Work plan for the joint CVMP/CHMP ad-hoc expert group on the application of the 3Rs (replacement, reduction and refinement) in regulatory testing of medicinal products (JEG 3Rs) 2013	adopted
EMA/CHMP/241120/2013	Reflection Paper on the data requirements for IV iron-based nano-colloidal products developed with reference to an innovator product	6-month public consultation